Hikari Power’s Corvus Pharmaceuticals CRVS Stock Holding History

Hikari Power’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$731K	Hold	49,959	–	–	0.06%	36
2025 Q4	$385K	Hold	49,959	–	–	0.03%	54
2025 Q3	$368K	Hold	49,959	–	–	0.03%	56
2025 Q2	$200K	Hold	49,959	–	–	0.02%	61
2025 Q1	$159K	Hold	49,959	–	–	0.01%	58
2024 Q4	$267K	Hold	49,959	–	–	0.02%	57
2024 Q3	$264K	Hold	49,959	–	–	0.02%	59
2024 Q2	$91K	Hold	49,959	–	–	0.01%	61
2024 Q1	$89K	Hold	49,959	–	–	0.01%	62
2023 Q4	$88K	Hold	49,959	–	–	0.01%	62
2023 Q3	$73K	Hold	49,959	–	–	0.01%	63
2023 Q2	$114K	Hold	49,959	–	–	0.01%	62
2023 Q1	$45K	Hold	49,959	–	–	﹤0.01%	65
2022 Q4	$42K	Hold	49,959	–	–	﹤0.01%	65
2022 Q3	$41K	Hold	49,959	–	–	﹤0.01%	66
2022 Q2	$49K	Hold	49,959	–	–	0.01%	66
2022 Q1	$82K	Buy	49,959 +30,000	+150%	+$54.9K	0.01%	67
2021 Q4	$48K	Hold	19,959	–	–	﹤0.01%	66
2021 Q3	$97K	Hold	19,959	–	–	0.01%	65
2021 Q2	$53K	Hold	19,959	–	–	0.01%	69
2021 Q1	$61K	Hold	19,959	–	–	0.01%	66
2020 Q4	$71K	Hold	19,959	–	–	0.01%	69
2020 Q3	$80K	Sell	19,959 -41,000	-67%	-$164K	0.01%	58
2020 Q2	$166K	Hold	60,959	–	–	0.02%	59
2020 Q1	$129K	Sell	60,959 -19,041	-24%	-$77.3K	0.02%	75
2019 Q4	$435K	Sell	80,000 -50,000	-38%	-$175K	0.05%	68
2019 Q3	$391K	Hold	130,000	–	–	0.04%	79
2019 Q2	$486K	Hold	130,000	–	–	0.05%	74
2019 Q1	$523K	Hold	130,000	–	–	0.05%	71
2018 Q4	$477K	Buy	130,000 +97,910	+305%	+$668K	0.05%	72
2018 Q3	$275K	Buy	+32,090	New	+$321K	0.03%	103

Other funds holding CRVS

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Hikari Power's CRVS Position: Q1 2026 in Review

Hikari Power held its Corvus Pharmaceuticals (CRVS) position steady in Q1 2026 at 49,959 shares worth $731K. The position accounts for 0.06% of the portfolio, ranked #36.

Hikari Power first reported a position in CRVS in Q3 2018 and has held it in 31 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

Hikari Power held 49,959 shares of Corvus Pharmaceuticals worth $731K as of Q1 2026.
Hikari Power left its Corvus Pharmaceuticals share count unchanged in Q1 2026.
Corvus Pharmaceuticals made up 0.06% of Hikari Power's portfolio in Q1 2026, its #36 holding.
Hikari Power first reported a position in Corvus Pharmaceuticals in Q3 2018 and has held it in 31 quarters since.
164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Hikari Power's 13F filing for Q1 2026, filed 30 Apr 2026.